EUVIMEDEUVIMED entdecken
Crossref

Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study

Asim Joshi, Abantika Ghosh, Prashant Rai, Sarika Tilwani, Venkataramanan Ramachandran, Kumar Prabhash, Mahul Amin, Prashant Kumar

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02461-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2024. Verfasst von Asim Joshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Karkinos Healthcare Pvt Ltd, 21st floor, Rupa Renaissance, D33, Turbhe MIDC road, Navi Mumbai, Maharashtra, 400705, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Cisplatin, Taxoids. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is a common malignancy worldwide, posing a substantial healthcare challenge. Current standard treatment regimens are primarily based on cisplatin, but their success is often limited by cisplatin resistance and associated toxicities. Therefore, there is an urgent need to develop effective and less toxic therapies as alternatives to cisplatin. We screened the activity of FDA-approved anti-cancer drugs on a panel of cisplatin-resistant bladder cancer cell lines. Based on initial responses, cabazitaxel was selected for further evaluation of its inhibitory effects on the phenotypic properties of these cells. Cabazitaxel, primarily used for metastatic castration-resistant prostate cancer, demonstrated remarkable efficacy in inhibiting colony formation, proliferation, and migration of cisplatin-resistant bladder cancer cells. This study highlights the potential of drug repurposing as a cost-effective and efficient strategy to overcome drug resistance in bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDrug Resistance, NeoplasmCisplatinTaxoidsAntineoplastic AgentsHumansCell Line, TumorCell ProliferationCell Movement

Stichwörter der Autor:innen

Bladder cancerCabazitaxelCisplatin resistanceDrug repurposing

Substanzen

cabazitaxelCisplatinTaxoidsAntineoplastic Agents

Autor:innen und Institutionen

  • Karkinos Healthcare Pvt Ltd, 21st floor, Rupa Renaissance, D33, Turbhe MIDC road, Navi Mumbai, Maharashtra, 400705, India.
  • Karkinos Foundation, Mumbai, Maharashtra, 400086, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India.
  • Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, 400094, India.
  • Department of Pathology and Laboratory Medicine, University of Tennessee Health Science, Memphis, TN, USA.
  • Karkinos Healthcare Pvt Ltd, 21st floor, Rupa Renaissance, D33, Turbhe MIDC road, Navi Mumbai, Maharashtra, 400705, India. prashant.kumar@karkinos.in.

Zitieren

APA

Joshi, A., Ghosh, A., Rai, P., Tilwani, S., Ramachandran, V., Prabhash, K., Amin, M., & Kumar, P. (2024). Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study. Medical Oncology. https://doi.org/10.1007/s12032-024-02461-y

Vancouver

Joshi A, Ghosh A, Rai P, Tilwani S, Ramachandran V, Prabhash K, et al. Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study. Medical Oncology. 2024. doi:10.1007/s12032-024-02461-y

BibTeX
@article{Joshi2024,
  author = {Joshi, Asim and Ghosh, Abantika and Rai, Prashant and Tilwani, Sarika and Ramachandran, Venkataramanan and Prabhash, Kumar and Amin, Mahul and Kumar, Prashant},
  title = {Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02461-y}
}
Kostenlos starten →